Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BrightEdge is the innovation and impact investment arm of the American Cancer Society, founded in 2018. It focuses on leveraging ACS's legacy in cancer research to invest in scalable solutions addressing unmet needs in cancer care. The firm operates globally and participates in funding stages from pre-seed to Series A.
BrightEdge invests in early-stage companies and technologies that provide patient-centric solutions in cancer care. Their strategy emphasizes technology-enabled solutions and science-based medicines, particularly in prevention, early detection, and treatment adherence. They aim to advance scientific discovery and reduce health disparities through strategic investments.
BrightEdge supports pioneering startups in cancer care, including Checkmate Pharmaceuticals, Castle Biosciences, Freenome, and TailorMed. They focus on ongoing value creation and generating financial returns to diversify ACS's funding sources.
BrightEdge runs the BrightEdge Entrepreneurs Program, an accelerator for first-time entrepreneurs in cancer research. They also manage Project HEALTH, which focuses on startups addressing disparities in cancer care, offering education and funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.